Serrapeptase: The Silkworm Enzyme for Inflammation and Mucus — What the Trials Show

Serrapeptase (serratiopeptidase) is a proteolytic enzyme produced by Serratia bacteria originally isolated from silkworm gut, where it dissolves the cocoon. It is sold over the counter as a "systemic enzyme" for sinusitis, fibrocystic breast disease, post-surgical swelling, atherosclerotic plaque, and chronic pain. The clinical literature is unevenly distributed: some specific surgical-recovery uses have decent trial support; many of the broader claims do not.

Where the evidence is best

The most cited body of work is in dental and ENT surgery. A meta-analysis of trials in dental surgery patients found that serratiopeptidase 5–10 mg three times daily reduced post-operative facial swelling and trismus compared with placebo, with effect sizes comparable to standard NSAIDs in some studies [1]. A separate body of work in chronic sinusitis and bronchitis showed reductions in sputum viscosity and improvements in expectoration [2]. These trials are mostly small and conducted in Italy, India, and Japan.

Where the evidence is weak or absent

Marketing claims that serrapeptase "dissolves arterial plaque," "removes scar tissue," or "breaks up fibrin" rest mainly on cell-culture and animal experiments. There are no controlled trials in humans demonstrating cardiovascular plaque regression, and no head-to-head comparison with statins or antiplatelet agents [3]. Use for atherosclerosis is speculative and substitutes for therapies with proven mortality benefit.

Pharmacology — does an oral protein survive digestion?

Serrapeptase is enteric-coated in commercial products to bypass gastric acid. Animal studies suggest that intact enzyme is detectable in lymph and serum after enteric-coated administration, but the absorbed fraction is small and the systemic half-life short [4]. The clinical effects observed in trials are real, but the mechanistic story (intact enzyme circulating and breaking down protein deposits anywhere in the body) probably oversimplifies what is happening.

Safety profile

In short trials (≤8 weeks) tolerability is good. The most reported side effects are mild GI upset, rash, and rare bleeding. There are case reports of pneumonitis, eosinophilic pneumonia, and anaphylaxis associated with serratiopeptidase use [5]. Anyone on anticoagulants, antiplatelets, or with a bleeding disorder should not use it without clinician input.

Regulatory and quality concerns

Serrapeptase was withdrawn from the prescription market in Japan in 2011 after a re-evaluation found it lacked sufficient efficacy data versus placebo for the indications it had been registered for [6]. It remains widely available as a supplement in the U.S. and Europe. Activity units (SU or SPU) are not standardised across manufacturers; potency varies significantly between brands.

Practical takeaway

A short 5–10 day course of enteric-coated serrapeptase (10 mg, 60,000 SU, three times daily) is reasonable as an adjunct after dental surgery or for symptomatic sinus mucus reduction in adults without bleeding risk. It is not a credible long-term therapy for cardiovascular disease, scar reduction, or chronic inflammation, and should not displace evidence-based therapy.

Comparing systemic enzyme products

"Systemic enzyme therapy" includes serrapeptase, nattokinase, bromelain, and lumbrokinase. They have different mechanisms: serrapeptase is a serine protease, nattokinase a fibrinolytic enzyme, bromelain a mix of cysteine proteases, lumbrokinase an earthworm-derived fibrinolytic. The trial evidence is uneven across them; bromelain has the most consistent post-surgical anti-inflammatory data, nattokinase the most cardiovascular biomarker work. Combining multiple systemic enzymes — common in marketed formulations — has not been shown to outperform single-enzyme products in head-to-head trials.

What "enteric-coated" actually means and why it matters

The enteric coating is a pH-sensitive polymer (typically methacrylate) that resists dissolution in stomach acid (pH 1–2) and dissolves in the more neutral environment of the small intestine (pH 6–7). Without it, oral protease enzymes are largely denatured by gastric acid and pepsin. Buying "serrapeptase" without an enteric coat means buying a product that is unlikely to deliver intact enzyme past the stomach. Reading the label for "enteric coated" or "delayed release" is a basic quality check.